Background: Circulating glycated albumin is a marker of blood glucose reflecting the previous 2 weeks. However, the effects of storage conditions and draw site on glycated albumin values are not fully understood.
| INTRODUCTION
Glycated albumin has a half-life in circulation of 14-17 days. 1 As a marker of blood glucose, 1 albumin undergoes permanent nonenzymatic glycation inline with the surrounding glucose concentration.
2,3
Although glycated albumin has an expanding presence in research, 4 and clinically, 5, 6 it is currently unknown if glycated albumin in plasma is subject to protein degradation, or additional glycation 7 when stored or exposed to common laboratory conditions. Furthermore, convenient screening of blood glucose within the population relies on portable devices that enable fast processing. The capacity to use capillary sampling instead of the more invasive venous sampling may increase the usefulness of glycated albumin as a marker of blood glucose.
To enable the development of standardization protocols for the assessment of glycated albumin, our objective was to consider its stability in plasma under common laboratory exposures. Our second objective was to consider variability in glycated albumin values when drawn from venous and capillary vascular sites.
| METHODOLOGY
Laboratory assessments were undertaken in July 2014 on de-identified samples. This research received ethical approval from the Health and Disability Ethics Committee of the University of Otago (H13/039).
Sample assessment was undertaken in Dunedin, New Zealand.
| Participants and sample preparation
Whole blood samples from 40 adults with type 2 diabetes participating in a randomized controlled trial 8 were collected over a 4-month period. All samples were drawn following a minimum 10-h fast. All blood samples were drawn from the median cubital vein unless specified as capillary samples. Capillary samples were collected from a fingertip with volumes >300 μL preferred. When capillary plasma volumes were inadequate for direct assessment, they were diluted 1:1 with deionized water.
All whole blood samples were collected in tubes containing potassium ethylenediaminetetraacetic acid (EDTA) and stored chilled for under 2 h before centrifugation at 1650 RCF for 5 min. Plasma was separated and then, unless assessed immediately, frozen at −80°C.
Samples remained frozen for up to 4 months before being thawed and assessed. To defrost samples, they were removed from −80°C, and kept stationary and capped at room temperature (16°C) for 2 h.
All samples were vortex mixed before assessment to homogenize the plasma matrix.
| Test procedures

| Test one: Storage at 4°C
Fifteen plasma samples of 3 mL were defrosted and kept at 4°C.
Glycated albumin values were assessed at 0, 12, 24, 48, and 72 h after defrost. Plasma samples remained immobile in the dark, and were capped with lids containing a rubber O ring for test duration.
| Test two: Freeze-thaw cycling
Fifteen plasma samples of 3 mL were assessed for glycated albumin within 2 h of being drawn (fresh, unfrozen), and then stored at −80°C.
Plasma samples were defrosted then refrozen at the same time each day for 10 days. Glycated albumin values were assessed after 1, 2, 5, and 10 freeze-thaw cycles.
| Test three: Capillary and venous assessment
Blood from 40 participants with type 2 diabetes was drawn from venous and capillary sites within 5 min of each other. Samples were centrifuged, with the plasma fraction stored at −80°C until assessment. Assessment of glycated albumin was undertaken in a randomized order.
| Sample measurement
Albumin and glycated albumin concentration of plasma samples were determined enzymatically on a COBAS C-311 centrifugal analyzer (Roche Diagnostics, Risch-Rotkreuz, Switzerland) with a Lucica GA-L assay kit (Asahi Kasei, Tokyo, Japan). The coefficient of variation (CV) for the manufacturer-supplied high and low controls were 1.3% and 1.2%, respectively. Three plasma samples as- 
| Statistical analysis
Two-sided paired t tests examined movement away from baseline in test one and two. A two-sided paired t test was used in test three to assess differences in albumin concentration between venous and capillary vascular sites. A Pearson's correlation coefficient assessed albumin concentration in plasma when diluted with deionized water.
Results are expressed as mean (SD) unless otherwise stated. A P value below .050 was considered significant.
| RESULTS
Baseline characteristics of participants diagnosed with type 2 diabetes who provided blood samples for analysis are shown in Table 1 . The test one (storage at 4°C over time) mean glycated albumin value at baseline was 17.4% (0.18). The CV for glycated albumin controls run during this test was 1.1%. As shown in Figure 1 albumin and the glycated fraction did not statistically differ at this time point.
The test two (freeze-thaw cycling) mean glycated albumin value at baseline was 18.2% (0.25). The CV for glycated albumin controls run during this test was 1.4%. As shown in Figure 2 , all three analytes remained stable during ten freeze-thaw cycles.
The test three (capillary and venous assessment) mean glycated albumin of venous samples was 18.5% (4.30), capillary samples (n=40) were 18.1% (4.69). The CV for glycated albumin controls run during this test was 1.87%. As shown in Figure 3 , differences existed in protein concentration between vascular sites, with capillary concentration lower for albumin (g/dL; P<.001) and glycated albumin (g/dL; P=.001) content. As both analyte concentrations were reduced in the capillary sample, the reported percentage of albumin glycation remained comparable between vascular sites (P=.379).
| DISCUSSION
Tests one and two were chosen to replicate common exposures in the laboratory that may influence glycated albumin content of plasma samples. These tests considered the activity of biological samples at low temperature 7 and the potential for structural damage in the transition between liquid and solid state. 10 The results of these tests will inform the development of standard protocols for the assessment of glycated albumin, and compliments previous research that indicates glycated albumin is stable when stored frozen over long periods of time. 11 This strengthens industry standards, confidence in measurement, and supports the comparison of glycated albumin values between clinical laboratories.
We assessed glycated albumin with enzymatic analysis on an autoanalyzer. Enzymatic methods for glycated albumin assessment enable efficient batch processing and are highly comparable with highperformance liquid chromatography methods. 9 It is important to note that when left uncapped on an autoanalyzer samples evaporated over time, potentially increasing glycated albumin values within a plasma sample. While this was controlled for in the current study by minimizing the time plasma samples were uncapped, we cannot discount this potential confounder in other studies reporting glycated albumin values from enzymatic analysis.
| Strengths and weakness
This research is a practical consideration of a potential confounder in the relationship between glycated albumin concentration and blood glucose control. The findings are highly relevant for laboratories and technical staff. The weakness of this research is that statistical processes such as a survival analysis would confer greater confidence in the analysis results. However, this is rarely performed given the number of samples and volume of reagents required. Some variability was observed in test one at the 48 h time point, leading to a significantly higher glycated albumin (%) value which we view would be less likely to occur were greater numbers of tests undertaken.
| Future research
Our work considered glycated albumin stability in plasma samples.
Future work should consider stability in serum, as serum may have higher rates of biological activity. Future work on lifestyle confounders of glycated albumin levels is also necessary, given the observed effect of smoking 12 or excess body weight. 13 Our findings suggest glycated albumin (%) may be measured with capillary sampling. In comparison the use of fructosamine, another measure of the previous 2 weeks blood glucose control, would likely produce a difference between these vascular sites, as the reported fructosamine value is dependent on plasma pool concentration. 3 Given the convenience of capillary sampling over venous, future research should consider portable capillary testing for glycated albumin (%) assessment.
| CONCLUSION
Our results suggest that biological activity in plasma samples does not alter glycated albumin analyte values when stored at 4°C for up F I G U R E 1 Mean changes in glycated albumin (%), albumin (g/dL), and glycated fraction (g/dL) of plasma samples over time when stored at 4°C (n = 15). Error bars represent standard deviation at each time point. * P < .050 F I G U R E 2 Mean changes in glycated albumin (%), albumin (g/dL), and glycated fraction (g/dL) of plasma samples during freeze-thaw cycles (n = 15). Error bars represent standard deviation at each time point to 3 days. Furthermore, plasma samples can undergo freeze-thaw cycling at least 10 times without any discernable change in glycated albumin values. These findings will contribute to the development of protocols for the routine assessment of glycated albumin in plasma.
Finally, glycated albumin (%) values are comparable between capillary and venous samples, an important finding should portable, fingerprick-based glycated albumin meters be developed.
